» Articles » PMID: 31622970

Prediction of Preeclampsia in Nulliparous Women According to First Trimester Maternal Factors and Serum Markers

Overview
Date 2019 Oct 18
PMID 31622970
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the performance of maternal risk factors (BMI and mean arterial pressure [MAP]) and first-trimester maternal serum markers in the early prediction of preeclampsia (PE) in nulliparous women.

Material And Methods: This was a case-cohort study based on a cohort of 14,207 nulliparous women. A total of 213 cases with term PE (from 37 weeks + 0 days) and 55 cases with preterm PE (before 37 weeks + 0 days) were identified and validated. Randomly, 449 controls were selected. Serum samples previously collected for the double test (pregnancy-associated plasma protein A [PAPP-A] and free β human chorionic gonadotrophin [hCGβ]) as part of the first-trimester screening program were retrieved and analyzed for placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and neutrophil gelatinase-associated lipocalin (NGAL). Concentrations were transformed to multiples of the median (MoM). Multivariate regression analysis was used for prediction models. Receiver-operating characteristics (ROC) curves were used for evaluation of the screening performance.

Results: In preterm PE, the PlGF (0.79 MoM), sFlt-1 (0.86 MoM), NGAL (1.15 MoM), and PAPP-A (0.89 MoM) medians were significantly altered. In term PE, PlGF (0.90 MoM) and NT-proBNP (0.86 MoM) medians were significantly reduced. The combination of MAP and PlGF yielded a 39% detection rate of preterm PE for a 10% false-positive rate. The combination of MAP, BMI, and PlGF yielded a 33% detection rate of term PE with a 10% false-positive rate.

Conclusion: First-trimester MAP, maternal serum PlGF, and NGAL are markers of preterm PE. Maternal serum sFlt-1 is a significant marker of preterm PE, but only early in the first trimester. First-trimester maternal serum NT-proBNP is not a predictor of PE. Screening performance for PE with these markers individually or in combination is modest.

Citing Articles

Identifying Predictor Variables for a Composite Risk Prediction Tool for Gestational Diabetes and Hypertensive Disorders of Pregnancy: A Modified Delphi Study.

Cowan S, Lang S, Goldstein R, Enticott J, Taylor F, Teede H Healthcare (Basel). 2024; 12(13).

PMID: 38998895 PMC: 11241067. DOI: 10.3390/healthcare12131361.


Machine Learning Algorithms Versus Classical Regression Models in Pre-Eclampsia Prediction: A Systematic Review.

Tiruneh S, Vu T, Rolnik D, Teede H, Enticott J Curr Hypertens Rep. 2024; 26(7):309-323.

PMID: 38806766 PMC: 11199280. DOI: 10.1007/s11906-024-01297-1.


Early-pregnancy N-terminal pro-brain natriuretic peptide level is inversely associated with hypertensive disorders of pregnancy diagnosed after 35 weeks of gestation.

Takahashi M, Suzuki L, Takahashi N, Hanaue M, Soda M, Miki T Sci Rep. 2024; 14(1):12225.

PMID: 38806648 PMC: 11133404. DOI: 10.1038/s41598-024-63206-5.


Novel Associations Between Mid-Pregnancy Cardiovascular Biomarkers and Preeclampsia: An Explorative Nested Case-Control Study.

Callbo P, Junus K, Gabrysch K, Bergman L, Poromaa I, Lager S Reprod Sci. 2024; 31(5):1391-1400.

PMID: 38253981 PMC: 11090924. DOI: 10.1007/s43032-023-01445-z.


Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia.

Schuermans A, Truong B, Ardissino M, Bhukar R, Slob E, Nakao T JAMA Cardiol. 2024; 9(3):209-220.

PMID: 38170504 PMC: 10765315. DOI: 10.1001/jamacardio.2023.4994.